Vol.20 No.6

Case Report

Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis

Authors

Kayoko Kaneko1 , Toshihiro Nanki1,2 , Tadashi Hosoya1 , Fumitaka Mizoguchi1 , Nobuyuki Miyasaka1

  • Department of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan
  • Department of Pharmacovigilance, Graduate School, Tokyo Medical and Dental University, Tokyo 113-8519, Japan
Received:

2 April 2010

Accepted:

15 June 2010

Published online:

9 July 2010

Full Text

PDF　(member's only)

Abstract

We present two patients with rheumatoid arthritis (RA) who developed necrotizing crescentic glomerulonephritis (NCGN) during etanercept therapy. Both patients developed proteinuria and hematuria, and one progressed to renal failure. Renal biopsy revealed NCGN. In both patients, nephritis improved following discontinuation of etanercept and administration of prednisolone. Physicians should be aware of etanercept-induced GN in patients with RA on anti-tumor necrosis factor therapy.

Key words

Antitumor necrosis factor therapy - Etanercept - Necrotizing crescentic glomerulonephritis - Rheumatoid arthritis